КАТЕТЕРНАЯ АБЛАЦИЯ ПАРОКСИЗМАЛЬНОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ У ПАЦИЕНТОВ С ПЕРЕНЕСЕННЫМ АМИОДАРОН-ИНДУЦИРОВАННЫМ ТИРЕОТОКСИКОЗОМ
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Полный текст:
Аннотация
Об авторах
Е. Н. МихайловРоссия
Д. С. Лебедев
Россия
В. С. Оршанская
Россия
Список литературы
1. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/ AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines // Circulation. - 2011. - V.123. - P.104-123.
2. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up: a report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation // Heart Rhythm. - 2007. - V.4(6). - P.816-861.
3. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation / J. Auer [et al.] // American Heart Journal. - 2001. - V.142. - P. 838-842.
4. Johnson PN, Freedberg AS, Marshall JM. Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits // Cardiology. - 1973. - V.58. - P.273-289.
5. Chen YC, Chen SA, Chen YJ, et al. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes // J. Am. Coll. Cardiol. - 2002. - V.39. - P.366-372.
6. Hai'ssaguerre M, Jai's P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci // Circulation. - 2000. - V.101. - P.1409-1417.
7. Lee SH, Tai CT, Hsieh MH, et al. Predictors of nonpulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation // J. Am. Coll. Cardiol. - 2005. - V.46. - P.1054-1059.
8. Pak HN, Hwang C, Lim HE, et al. Electroanatomic characteristics of atrial premature beats triggering atrial fibrillation in patients with persistent versus paroxysmal atrial fibrillation // J. Cardiovasc. Electrophysiol. - 2006. - V.17. - P.818-824.
9. SAUER WH, ALONSO C, MCKERNAN ML, ET AL. Female gender is associated with the presence of non-pulmonary vein triggers of atrial fibrillation // Circulation. -2003. - V. 108. - Suppl. IV. - P.IV617.
10. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation // Circulation. - 2010. - V.122(2). - P.109-118.
11. Pappone C, Manguso F, Vicedomini G, et al. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach // Circulation. - 2004. - V.110. - P.3036-3042.
12. Ma CS, Liu X, Hu FL, et al. Catheter ablation of atrial fibrillation in patients with hyperthyroidism // J. Interv. Card. Electrophysiol. - 2007. - V.18(2). - P.137-142.
13. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state // American Journal of Medicine. - 1982. - V.72. - P.903-906.
14. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats // Circulation. - 1995. -V.92. - P.1954-1968.
15. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid // Endocr. Rev. - 2001. - V.22. - P.240-254.
16. Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone // Endocrinology. - 1994. - V.134(5). - P. 2277-2282.
17. Beddows SA, Page SR, Taylor AH, et al. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes // Biochem. Pharmacol. - 1989. - V.38(24). -P.4397-4403.
18. Cohen-Lehman J, Dahl S, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function // Nature reviews endocrinology. - 2010. - V.6. - P.34-41.
19. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases // Clin. Endocrinol. (Oxf.). - 1987. - V.26. - P.227-237.
20. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy // Ann. Intern. Med. - 1984. -V.101. - P.28-34.
21. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function // Ann. Intern. Med. - 1997. - V.126. - P.163-173.
22. Sidhu J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK // QJM. - 2003. - V.96. - P.949-950.
23. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism // Am. J. Med. - 1991. - V.91. - P.507-511.
24. Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology // Thyroid. - 1998. - V.8. - P.83-100.
Рецензия
Для цитирования:
Михайлов Е.Н., Лебедев Д.С., Оршанская В.С. КАТЕТЕРНАЯ АБЛАЦИЯ ПАРОКСИЗМАЛЬНОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ У ПАЦИЕНТОВ С ПЕРЕНЕСЕННЫМ АМИОДАРОН-ИНДУЦИРОВАННЫМ ТИРЕОТОКСИКОЗОМ. Вестник аритмологии. 2011;66(66):35-41.
For citation:
Mikhaylov E.N., Lebedev D.S., Orshanskaya V.S. CATHETER ABLATION OF PAROXYSMAL ATRIAL FIBRILLATION IN PATIENTS WITH THE HISTORY OF AMIODARONE-INDUCED HYPERTHYROIDISM. Journal of Arrhythmology. 2011;66(66):35-41. (In Russ.)
ISSN 2658-7327 (Online)